BeiGene, Ltd. or Corcept Therapeutics Incorporated: Who Manages SG&A Costs Better?

SG&A Cost Management: BeiGene vs. Corcept

__timestampBeiGene, Ltd.Corcept Therapeutics Incorporated
Wednesday, January 1, 2014693000034916000
Thursday, January 1, 2015731100036949000
Friday, January 1, 20162009700045240000
Sunday, January 1, 20176260200062416000
Monday, January 1, 201819538500081289000
Tuesday, January 1, 2019388249000100359000
Wednesday, January 1, 2020600176000105326000
Friday, January 1, 2021990123000122356000
Saturday, January 1, 20221277852000152848000
Sunday, January 1, 20231504501000184259000
Loading chart...

In pursuit of knowledge

Managing SG&A Costs: A Tale of Two Biotechs

In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. BeiGene, Ltd. and Corcept Therapeutics Incorporated, two prominent players, offer a fascinating study in contrasts. Over the past decade, BeiGene's SG&A expenses have skyrocketed, increasing by over 21,000% from 2014 to 2023. This reflects their aggressive expansion strategy, aiming to capture a larger market share. In contrast, Corcept Therapeutics has maintained a more conservative growth, with SG&A expenses rising by approximately 428% in the same period. This suggests a focus on sustainable growth and cost efficiency. As of 2023, BeiGene's SG&A expenses are over eight times higher than Corcept's, highlighting their differing approaches. Investors and industry watchers should consider these strategies when evaluating the long-term potential of these companies.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025